PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Eli Lilly & Company Ltd
EL

Eli Lilly & Company Ltd

UK public-sector supplier
Large

Eli Lilly and Company Ltd is the UK subsidiary of Eli Lilly and Company, a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines in the areas of diabetes, oncology, immunology, and neuroscience. In the UK, Lilly supplies innovative medicines to the NHS including treatments for diabetes (insulin and GLP-1 receptor agonists), cancer, and autoimmune conditions. The company invests significantly in clinical research and works closely with NICE and NHS England on medicines access and value-based agreements.

lilly.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£519.8m
Live
31
Buyers
6
12m
£166.3m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts31 / 64
  • Top buyers6
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Eli Lilly & Company LtdUpdated 20 Jul 2026

At a glance · for buyers and watchdogs

Eli Lilly & Company Ltd has won £519.8m across 6 public-sector buyers, with 31 live contracts.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
No CH recordCompany status
31 of 64Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 2/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment✓
Tackling inequalityNo commitment stated✓
Community1 commitment✓
Environment · 1
  • WebsiteNet zero target2040
Community · 1
  • WebsiteSocial valueAdvancing healthcare through pharmaceutical innovation

Extracted automatically from lilly.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 8
Diabetes Medicines
Oncology Medicines
Immunology Medicines
Neuroscience Medicines
Insulin Products
GLP-1 Receptor Agonists
Clinical Research
Pharmaceutical Manufacturing
Frameworks & DPS · 6 from notices
  • NHS England Framework Agreement: South of England (Tranche B)NHS England · £15.7m
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS England Framework Agreement - London - Tranche ANHS England · £10.6m
  • NHS Framework Agreement for Proprietary Pharmaceuticals - South of England (Tranche A)NHS England · £10.5m
  • NHS England - Midlands and East Branded Medicines - Tranche BNHS England · £9.2m
  • NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder OpportunityNHS England · £8.4m

Extracted automatically from lilly.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships · 2

Credentials listed on the supplier’s website. Not yet checked against issuer registers.

◐ From supplier website
Core credentials · 1/6
Cyber EssentialsNot evidenced✓
Cyber Essentials PlusNot evidenced✓
ISO 27001 — Information securityNot evidenced✓
ISO 9001 — QualityNot evidenced✓
ISO 14001 — EnvironmentalListed on site✓
ISO 45001 — Health & safetyNot evidenced✓
Other credentials & memberships · 1
GMP Compliance

Extracted automatically from lilly.com on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 31 live · 33 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
NHS England—01 Sept 2026£166.3m2 yrspending
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National
NHS England3360000001 Sept 2025£9.4m2 yrsLive
NHS Branded Medicines Tranche Framework for London and South of England
NHS England3360000001 Sept 2024£13.1m2 yrsLive
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024
NHS England3360000001 May 2024£11.2m4 yrsLive
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
NHS England3360000001 Mar 2024£17.6m2.5 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
NHS London Branded Medicines - Tranche B - September 2023
NHS England3360000001 Sept 2023£6.4m2 yrsClosed
NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
NHS England3360000001 May 2023£6.1m2 yrsClosed
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche
NHS England3360000001 Mar 2023£13.7m2 yrsClosed
NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche
NHS England3360000001 Mar 2023£9.0m2 yrsClosed
Total live value £51.3m · mean award £8.1m1–10 of 64

Top buyers · 6 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
51 contracts
100%
since 2017
2
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
4 contracts
0%
3
eTenderwales
2 contracts
0%
4
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
2 contracts
0%
5
The NHS Commissioning Board (operating under the name of NHS England)
4 contracts
0%
6
BELFAST HEALTH AND SOCIAL CARE TRUST
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire51 contracts
100%
Scotland4 contracts
0%
Wales4 contracts
0%
North West4 contracts
0%
Northern Ireland1 contract
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Eli Lilly & Company Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
EL
Eli Lilly & Company Ltd
No£166.3m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m20
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m13
TA
Thornton and Ross Ltd
Yes£72.5m11
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
No Companies House record linked — automated risk checks unavailable.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
No Companies House record linked — statutory compliance checks unavailable.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Registered details, directors and PSC.

✓ Live sync
🏛

No Companies House record linked

No Companies House number on file — this supplier may be overseas, a sole trader or a consortium.

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
—
— · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.